Publications by authors named "N Held"

Objective: The objective of this scoping review was to investigate the available literature on physical and quality of life (QoL) outcomes of underwater treadmill exercise trials in clinical chronic pain samples.

Methods: A scoping search of studies of the effectiveness of underwater treadmill exercise trials from 1947 to 2024 was conducted using the following databases: EMBASE, MEDLINE, SPORTDiscus, CINAHL, and Cochrane Reviews. To be included, studies were required to have included adult participants living with chronic pain (defined as pain lasting for 3 months or longer) who participated in an active underwater treadmill exercise intervention.

View Article and Find Full Text PDF

Resource availability dictates how fast and how much microbial populations grow. Quantifying the relationship between microbial growth and resource concentrations makes it possible to promote, inhibit, and predict microbial activity. Microbes require many resources, including macronutrients (e.

View Article and Find Full Text PDF
Article Synopsis
  • Sacituzumab govitecan (SG) is effective for treating metastatic triple-negative breast cancer (mTNBC), with a median overall survival of 9.6 months in heavily pretreated patients.
  • A study of 115 female patients showed that over half experienced significant adverse events, leading to dose adjustments in over half of the cases.
  • For patients with HER2-low mTNBC receiving trastuzumab deruxtecan (T-DXd) after SG, the objective response rate was 34.8%, indicating that sequential treatments can be beneficial.
View Article and Find Full Text PDF

Background: Pembrolizumab combined with neoadjuvant chemotherapy (NAC) is the current standard of care in early stage triple-negative breast cancer (TNBC) based on higher event-free survival and pathological complete response (pCR) in Keynote-522 (KN-522) clinical trial. However, this aggressive five-drug regimen is associated with increased risks for immune-related adverse events (irAEs). We investigated real-world clinical outcomes and toxicity of this regimen as well as factors predictive of pCR and irAEs.

View Article and Find Full Text PDF

Progressive inflammation of one hemisphere characterises Rasmussen's encephalitis (RE), but contralesional epileptiform activity has been repeatedly reported. We aimed to quantify contralesional epileptiform activity in RE and uncover its functional and structural underpinnings. We retrospectively ascertained people with RE treated between 2000 and 2018 at a tertiary centre (Centre 1) and reviewed all available EEG datasets.

View Article and Find Full Text PDF